Seretide is indicated in the regular treatment of asthma where use of a combination product (long-acting β2 agonist and inhaled corticosteroid) is appropriate:
The recommended dose of Seretide Evohaler 50/25, 125/25 or 250/25 is two inhalations, twice daily.
Seretide Evohaler comes in three different doses, allowing flexibility of dosing for your patient with asthma at low, medium and high dose inhaled steroid4
Seretide Evohaler 50/25 is licensed for use in paediatric asthma for patients 4 years and above.4
Low Dose (50/25 two puffs B.D)
Medium Dose (125/25 two puffs B.D)
over £5 cheaper than Fostair 100/6 (two puffs B.D)1,2
High Dose (250/25 two puffs B.D)
same price as Fostair 200/6 (two puffs B.D)2,5
Seretide is proven to achieve and maintain guideline-defined asthma control3
*GOAL Study Stratum 2 patients defined as those patients who were on 500 μg or less of beclomethasone propionate daily or equivalent.
Patients should not need their rescue inhaler
6 days a week6
rescue free days with Seretide*6
*GOAL Study Stratum 2 patients defined as those patients who were on 500 μg or less of beclomethasone propionate daily or equivalent. The GOAL data has been extrapolated from over one year into one week.
Seretide Evohaler is over £5 cheaper than Fostair at medium dose1,2, and is the same price as Fostair at high dose2,5
|Low||50/25 (2 puffs B.D)||100/6 (1 puff B.D)|
|Medium||125/25 (2 puffs B.D)||100/6 (2 puffs B.D)|
|High||250/25 (2 puffs B.D)||200/6 (2 puffs B.D)|
Seretide Evohaler 50/25 has a license for paediatric asthma for patients 4 years and above, and all
strengths are licensed in adolescent asthma4.
Fostair is not recommended for children & adolescents under 18 years9
The optimal particle size range for delivery to the lungs is 1-5um. Seretide particles are within this range10
There is no evidence that extrafine particles are associated with additional clinically relevant benefits compared with Seretide11,12
This was observed for a number of efficacy endpoints in an extensive scientific literature review and systematic analysis of RCT data, including:
Therefore you can be confident that particle size does not need to be a factor when choosing between Seretide and Fostair.
When clinically indicated, maintenance and reliever therapy (MART) can be a viable option for patients. However, are you aware of some of its limitations?
Less than 20% of MART-treated patients achieved control, according to GINA criteria13,14
MART-treated patients are only rescue free 4 days a week and many still use a separate reliever15
1 in 5 MART-treated patients have a severe exacerbation each year15
Provides a numerical score that helps healthcare professionals and their patients determine if asthma symptoms are well controlled.Order now
This Placebo Demonstration Device helps healthcare professionals show patients how to use the Evohaler device correctly.Order now
How to Use Patient Leaflet Pad to support patients to correctly use their Evohaler on its own and with a Volumatic Spacer.Order now
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GlaxoSmithKline on 0800 221 441.
Seretide is a registered trademark of the GlaxoSmithKline group of companies
PM-GB-FPS-WCNT-200001 February 2020